Evidence map›Paper›PMID 35718629›Full record

ArticleAmerican journal of preventive medicine2022

Use and Impact of Type 2 Diabetes Prevention Interventions.

Joanne R Campione, Natalie D Ritchie, Howard A Fishbein, Russell E Mardon, Maurice C Johnson, Wilson Pace, Rebecca Jeffries Birch, Eileen L Seeholzer, Xuanping Zhang, Krista Proia and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Prediabetes.Nature reviews. Disease primers · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Joanne R CampioneWestat, Inc., Durham, North Carolina. Electronic address: joannecampione@westat.com.
Natalie D RitchieOffice of Research, Denver Health and Hospital Authority, Denver, Colorado.
Howard A FishbeinWestat, Inc. Rockville, Maryland.
Russell E MardonWestat, Inc. Rockville, Maryland.
Maurice C JohnsonWestat, Inc. Rockville, Maryland.
Wilson PaceDARTNet Institute, Aurora, Colorado.
Rebecca Jeffries BirchWestat, Inc. Rockville, Maryland.
Eileen L SeeholzerMetroHealth, Cleveland, Ohio.
Xuanping ZhangCenters for Disease Control and Prevention, Atlanta, Georgia.
Krista ProiaCenters for Disease Control and Prevention, Atlanta, Georgia.
Karen R SiegelCenters for Disease Control and Prevention, Atlanta, Georgia.
Kai McKeever BullardCenters for Disease Control and Prevention, Atlanta, Georgia.
Westat (United States) · USCenters for Disease Control and Prevention · USDenver Health Medical Center · USMetroHealth · US

Funding

Enhanced enrollment in the National Diabetes Prevention Program for the underserved: a randomized control trialR01DK119478 · NIDDK · DENVER HEALTH AND HOSPITAL AUTHORITY · PI PEREIRA, ROCIO INES · 2019 to 2023
$2.8M
NIDDK NIH HHS R01 DK119478
6 · The paper itself

Abstract

introductionRCTs have found that type 2 diabetes can be prevented among high-risk individuals by metformin medication and evidence-based lifestyle change programs. The purpose of this study is to estimate the use of interventions to prevent type 2 diabetes in real-world clinical practice settings and determine the impact on diabetes-related clinical outcomes.

methodsThe analysis performed in 2020 used 2010‒2018 electronic health record data from 69,434 patients aged ≥18 years at high risk for type 2 diabetes in 2 health systems. The use and impact of prescribed metformin, lifestyle change program, bariatric surgery, and combinations of the 3 were examined. A subanalysis was performed to examine uptake and retention among patients referred to the National Diabetes Prevention Program.

resultsMean HbA1c values declined from before to after intervention for patients who were prescribed metformin (-0.067%; p<0.001) or had bariatric surgery (-0.318%; p<0.001). Among patients referred to the National Diabetes Prevention Program lifestyle change program, the type 2 diabetes postintervention incidence proportion was 14.0% for nonattendees, 12.8% for some attendance, and 7.5% for those who attended ≥4 sessions (p<0.001). Among referred patients to the National Diabetes Prevention Program lifestyle change program, uptake was low (13% for 1‒3 sessions, 15% for ≥4 sessions), especially among males and Hispanic patients.

conclusionsFindings suggest that metformin and bariatric surgery may improve HbA1c levels and that participation in the National Diabetes Prevention Program may reduce type 2 diabetes incidence. Efforts to increase the use of these interventions may have positive impacts on diabetes-related health outcomes.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsMetforminAdolescentAdultBariatric SurgeryFemaleGlycated HemoglobinHumansLife StyleMaleGlycated HemoglobinHypoglycemic AgentsMetformin

Identifiers

PMID35718629
PMCPMC10015596
OpenAlexW4283029483

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.